Seagen

{{About|the American biotechnology company|the first large scale commercial tidal stream generator|SeaGen}}{{See also|Szczawin, Lower Silesian Voivodeship}}

{{Multiple issues|

}}

{{Infobox company|

| name = Seagen Inc.

| logo = Seattle Genetics logo.svg

| former_name = Seattle Genetics, Inc.
(1997–2020)

| type = Subsidiary

| parent = Pfizer

| traded_as = {{NASDAQ was|SGEN}}

| founded = {{start date and age|1997}}

| location = Bothell, Washington, U.S.

| key_people = {{unbulleted list|David R. Epstein|{{small|(Chief Executive Officer)}}|Roger Dansey M.D.|{{small|(President, Research and Development)}}|Todd E. Simpson|{{small|(Chief Financial Officer)}}}}

| industry = Biotechnology, pharmaceutical

| products = Brentuximab vedotin and other antibody-drug conjugates

| revenue = {{increase}} {{US$|1.96 billion|link=yes}} (2022)

| operating_income = {{increase}} {{US$|-613 million}} (2022)

| net_income = {{increase}} {{US$|-610 million}} (2022)

| assets = {{decrease}} {{US$|3.67 billion}} (2022)

| equity = {{decrease}} {{US$|2.80 billion}} (2022)

| num_employees = 3,256 (2022)

| website = {{URL|seagen.com}}

| footnotes = {{cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001060736/000106073623000009/sgen-20221231.htm |title= Seagen Inc. 2022 Annual Report (Form 10-K) |date=February 15, 2023 |publisher=U.S. Securities and Exchange Commission}}{{cite web |url=https://www.sec.gov/Archives/edgar/data/1060736/000106073622000025/sgen2022proxy.htm#i5ac9a66d40664f71ae549d2f827e50df_1725 |title=Seagen Inc. 2023 Proxy Statement |date=March 20, 2022 |publisher=U.S. Securities and Exchange Commission}}

}}

Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

The company's flagship product Adcetris (brentuximab vedotin)[http://adcreview.com/brentuximab-vedotin-sgn35/ brentuximab vedotin (SGN35)], ADC Review/Journal of Antibody-drug Conjugates is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.

To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program[http://adcreview.com/brentuximab-vedotin-adcetris-clinical-trials/ Brentuximab vedotin (ADCETRIS®) Clinical Trials], ADC Review/Journal of Antibody-drug Conjugates

to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.

In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies.

In January 2018, the company announced it would acquire Cascadian Therapeutics for $614 million.{{Cite web|url=https://www.genengnews.com/gen-news-highlights/seattle-genetics-to-acquire-cascadian-therapeutics-for-614m/81255441|title = Seattle Genetics to Acquire Cascadian Therapeutics for $614M|date = 31 January 2018}}

In September 2020, Merck & Co announced it would purchase $1 billion of Seagen's common stock, with both companies co-developing lead treatment: ladiratuzumab vedotin.[https://web.archive.org/web/20200914130511/https://uk.reuters.com/article/us-seattle-genetics-stake-merck-co/merck-to-buy-1-bln-stake-in-seattle-genetics-co-develop-cancer-therapy-idUKKBN2651Q7 Reuters]

In November 2022, the company announced the appointment of David R. Epstein as Chief Executive Officer and Director.{{Cite web |title=Seagen Names David R. Epstein as Chief Executive Officer and Director |url=https://investor.seagen.com/press-releases/news-details/2022/Seagen-Names-David-R.-Epstein-as-Chief-Executive-Officer-and-Director/default.aspx |access-date=2022-11-21 |website=investor.seagen.com |language=en-US |archive-date=21 November 2022 |archive-url=https://web.archive.org/web/20221121184919/https://investor.seagen.com/press-releases/news-details/2022/Seagen-Names-David-R.-Epstein-as-Chief-Executive-Officer-and-Director/default.aspx |url-status=dead }}

Pfizer agreed to acquire Seagen in March 2023.

Collaboration agreements

Seattle Genetics has collaboration agreements with Takeda Oncology Company (formerly Millennium) to develop and commercialize brentuximab vedotin. The company also has collaboration agreements for their ADC technology with a number of biotechnology and pharmaceutical companies, including AbbVie, Bayer Celldex Therapeutics, Inc., Daiichi Sankyo, Genentech, Inc., GlaxoSmithKline, Pfizer, Inc., and PSMA Development Company LLC, as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, and Oxford BioTherapeutics Ltd.[https://www.reuters.com/finance/stocks/companyProfile?symbol=SGEN.O Seattle Genetics Corporate Profile] Reuters

Technology

=MMAE-based=

Seattle Genetics' proprietary monomethyl auristatin E or MMAE-based antibody-drug conjugate technology, employed in brentuximab vedotin, empowers monoclonal antibodies to treat cancer. Brentuximab vedotin, for example, links the chimeric anti-CD30 monoclonal antibody (cAC10) via a protease-cleavable linker to MMAE. This ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. This approach is intended to spare non-targeted (healthy) cells and thus reduce many of the toxic effects of traditional chemotherapy while potentially enhancing antitumor activity. (See also vedotins)

History

=Early years=

Seattle Genetics was founded in 1997, by Henry Perry Fell, Jr.{{Cite web|url=http://www.thewfund.com/team/perry-fell#:~:text=Perry%20Fell%20is%20currently%20Chairman,served%20as%20CEO%20and%20President.|title = Team - Perry Fell - W Fund}} and Clay Siegall,{{Cite journal|last=Wright|first=Rob|date=13 February 2018|title=Seattle Genetics Legacy Of Partnering|url=https://www.lifescienceleader.com/doc/seattle-genetics-legacy-of-partnering-0001|journal=Life Science Leader|access-date=22 February 2018}} and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and prior to its acquisition by Pfizer, it was traded on the Nasdaq Stock Market under the symbol SGEN, and was a component of the Nasdaq-100. As of December 2016, the company has more than 900 employees throughout the United States.{{Cite news|url=https://seekingalpha.com/article/4044677-seattle-genetics-sgen-q4-2016-results-earnings-call-transcript|title=Seattle Genetics (SGEN) Q4 2016 Results - Earnings Call Transcript|last=Transcripts|first=SA|date=2017-02-10|work=Seeking Alpha|access-date=2018-01-10|language=en-US}}{{Cite news|url=https://www.seattletimes.com/business/technology/seattle-genetics-aims-to-put-drug-on-the-front-line-of-battling-cancer/|title=Seattle Genetics aims to put drug on the front line of battling cancer|date=2016-12-17|work=The Seattle Times|access-date=2018-01-10|language=en-US}}

=2009=

:19 February: pivotal trial for brentuximab vedotin for Hodgkin lymphoma[https://archive.today/20131221161003/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1258028&highlight= Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma] – Corporate Press Release

:18 June: Phase II trial of brentuximab vedotin for anaplastic large cell lymphoma[https://archive.today/20131221161048/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1300318&highlight= Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma] – Corporate Press Release

:24 July: initiation of re-treatment clinical trial of brentuximab vedotin[https://archive.today/20131221161103/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1311479&highlight= Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial] – Corporate Press Release

:10 August: milestone achievement in collaboration with MedImmune through initiation of Phase I clinical trial of MEDI-547.[https://archive.today/20131221161002/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1319058&highlight= Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune] – Corporate Press Release{{cite journal | pmid = 22370972 | doi=10.1007/s10637-012-9801-2 | volume=31 | title=Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors | pmc=3553417 | journal=Invest New Drugs | pages=77–84 | last1 = Annunziata | first1 = CM | last2 = Kohn | first2 = EC | last3 = LoRusso | first3 = P | last4 = Houston | first4 = ND | last5 = Coleman | first5 = RL | last6 = Buzoianu | first6 = M | last7 = Robbie | first7 = G | last8 = Lechleider | first8 = R| year=2013 | issue=1 }}

:8 September: milestone achievement in collaboration with Bayer for the submission of investigational new drug application with the FDA[https://archive.today/20131221161026/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1328785&highlight= Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma] – Corporate Press Release

:5 October: discontinuation of Phase IIb trial with dazcetuzumab (also known as SGN-40 or huS2C6) for the treatment of diffuse large B-cell lymphoma[https://archive.today/20131221161024/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1338211&highlight= Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial] – Corporate Press Release

:16 November: initiation of Phase I clinical trial for SGN-75 (INN: vorsetuzumab mafodotin)[https://archive.today/20131221161100/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1355709&highlight= Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75] – Corporate Press Release

:11 December: termination of collaboration with Genentech for SGN-40[https://archive.today/20131221161047/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1364992&highlight= Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)] – Corporate Press Release

:21 December: announcement of new collaboration with GlaxoSmithKline ($12 million up front payment, up to $390 million in milestone payments)[https://archive.today/20131221161039/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1368209&highlight= Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline] – Corporate Press Release

In 2009, when it appeared that ADCETRIS could reach the market, the company realized that commercial skills would need to be grown in-house and/or acquired. This led to a decision to grow a commercial team to address the United States and Canadian markets, and a marketing collaboration with Takeda to cover the rest of the world. By 2018, however, the company was confident it could conduct a global commercialization venture.

=2010=

:2 February: initiation of phase I combination clinical trial of brentuximab vedotin (SGN-35) for Hodgkin lymphoma[https://archive.today/20131221161059/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1382479&highlight= Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma] – Corporate Press Release

:3 March: milestone achievement under collaboration with Genentech[https://archive.today/20131221161102/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1398149&highlight= Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech] – Corporate Press Release

:8 April: initiation of Phase III trial for brentuximab vedotin (SGN-35) for post transplant Hodgkin lymphoma[https://archive.today/20131221161100/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1410768&highlight= Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma] – Corporate Press Release

:20 April: $9.5 million payment from Genentech to extend collaboration[https://archive.today/20131221161047/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1414864&highlight= Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration] – Corporate Press Release

:20 July: initiation of Phase I clinical trial of ASG-5ME for treatment of pancreatic cancer[https://archive.today/20131221161030/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1449324&highlight= Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer] – Corporate Press Release

:3 August: expansion of collaboration with Genentech ($12 million upfront payment, up to $900 million in potential fees and milestone payments)[https://archive.today/20131221161039/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1455493&highlight= Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech] – Corporate Press Release

:2 September: milestone achievement in collaboration with Agensys for initiation of Phase I trial of AGS-16M8F[https://archive.today/20131221161101/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1466352&highlight= Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas] – Corporate Press Release[http://cancerres.aacrjournals.org/content/70/8_Supplement/2436 Abstract 2436: AGS-16M8F is a novel antibody drug conjugate (ADC) for treating renal and liver cancers; Gudas JM, Torgov M, An Z, Jia XC, Morrison KJ, Morrison RK, Yang P, et al.] Cancer Res April 15, 2010 70; 2436. Last Accessed: February 15, 2011

:14 September: entry into collaboration with Genmab[https://archive.today/20131221161102/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1470819&highlight= Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration] – Corporate Press Release

:20 October: initiation of Phase I clinical trial of ASG-5ME in prostate cancer treatment[https://archive.today/20131221161023/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1484865&highlight= Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer] – Corporate Press Release

=2011=

:6 January: entry into collaboration with Pfizer ($8 million upfront payment, $200+ million in potential milestone payments)[https://archive.today/20131221161023/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1513501&highlight= Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Pfizer] – Corporate Press Release

:1 March: initiation of Phase I clinical trial of brentuximab vedotin for use in conjunction with chemotherapy for treatment of systemic anaplastic large cell lymphoma[https://archive.today/20131221161030/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1534179&highlight= Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL] – Corporate Press Release

:15 March: expansion of collaboration with the Millennium Pharmaceuticals (Takeda Oncology)[https://archive.today/20131221161103/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1539342&highlight= Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration] – Corporate Press Release

:22 March: announcement of collaboration with Abbott ($8 million upfront payment, plus potential royalties and milestone payments)[https://archive.today/20131221161058/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1541540&highlight= Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott] – Corporate Press Release

:11 April: James Fan, SG manager of clinical programming, commits suicide one day after being indicted for insider trading in Seattle Genetics securities[https://www.seattletimes.com/business/lure-of-riches-leads-to-suicide-in-seattle-genetics-stock-case/ Lure of riches leads to suicide in Seattle Genetics stock case | The Seattle Times]{{Cite web|url=https://www.dailyherald.com/article/20121118/business/711159832/|title=Suicide points to wave of insider trading in health industry|date=18 November 2012}}

:19 April: expansion of collaboration with Genmab[https://archive.today/20131221161039/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1551750&highlight= Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration] – Corporate Press Release

:19 August accelerated FDA approval for brentuximab vedotin for use in treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL)[https://archive.today/20131221161030/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1598466&highlight= Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS(TM) (Brentuximab Vedotin) for Two Indications] – Corporate Press Release

:23 August: initiation of Phase II trial of ADCETRIS in CD30-positive non-Hodgkin lymphoma[https://archive.today/20131221161030/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1599232&highlight= Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Hodgkin Lymphoma] – Corporate Press Release

:9 September: collaboration with Oxford BioTherapeutics[https://archive.today/20131221161039/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1606185&highlight= Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer] – Corporate Press Release

:25 October: initiation of Phase II clinical trial of ADCETRIS in CD30-positive non-lymphoma malignancies[https://archive.today/20131221161100/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1621132&highlight= Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Lymphoma Malignancies] – Corporate Press Release

=2012=

:4 June: interim Phase I data from ASG-5ME in prostate cancer[https://www.astellas.us/docs/us/ASG-5ME_Release_FINAL_04June12.pdf Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer] Astellas Press Release

:5 July: initiation of global Phase III trial of ADCETRIS against CD30-expressing cutaneous T-cell lymphoma[https://archive.today/20131221161003/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1692283&highlight= Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma] – Corporate Press Release

:24 August: initiation of Phase Ib trial of SGN-75 (INN: vorsetuzumab mafodotin) for use in combination with everolimus in patients with renal cell carcinoma[https://archive.today/20131221161101/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1728384&highlight= Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma] – Corporate Press Release

:9 October: milestone achievement under collaboration with Genentech by advancements of two antibody conjugates into Phase II trials[https://archive.today/20131221161030/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1743118&highlight= Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development] – Corporate Press Release

:17 October: initiation of Phase II trial of ADCETRIS in age 60+ Hodgkin lymphoma patients[https://archive.today/20131221161058/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1746448&highlight= Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS® as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over] – Corporate Press Release

:23 October: expansion of collaboration with Abbott (upfront payment of $25 million, milestone payment up to $220 million)[https://archive.today/20131221161002/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1748678&highlight= Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Abbott] – Corporate Press Release

:1 November: initiation of global Phase III trial of ADCETRIS in untreated advanced Hodgkin lymphoma patients[https://archive.today/20131221161030/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1752808&highlight= Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma] – Corporate Press Release

:26 November: received orphan drug designation for ADCETRIS treatment of mycosis fungoides[https://archive.today/20131221161103/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1761532&highlight= Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides] – Corporate Press Release

=2013=

:1 February: Health Canada approves ADCETRIS for treatment of relapsed refractory Hodgkin lymphoma[https://archive.today/20131221161103/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1780634&highlight= Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)] – Corporate Press Release

:6 February: initiation of two Phase I trials of SGN-CD19A[https://archive.today/20131221161101/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1782101&highlight= Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A] – Corporate Press Release

:25 June: new collaboration with Bayer[https://archive.today/20131221161059/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1832601&highlight= Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer] – Corporate Press Release

:15 July: initiation of Phase I trial of SGN-CD33A in treatment of acute myeloid leukemia (AML)[https://archive.today/20131221161040/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1837605&highlight= Seattle Genetics Initiates Phase 1 Trial of SGN-CD33A in Acute Myeloid Leukemia (AML)] – Corporate Press Release

:15 August: initiation of Phase II trial of ADCETRIS for diffuse large B-cell lymphoma[https://archive.today/20131221161047/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1847878&highlight= Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma (DLBCL)] – Corporate Press Release[http://www.cancer.gov/dictionary?cdrid=444967 B-cell lymphoma] NCI Dictionary of Cancer Terms; Last Accessed February 18, 2015

:21 October: initiation of Phase I trial of SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer[https://archive.today/20131221161003/http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1866281&highlight= Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer] – Corporate Press Release[http://adcreview.com/blog/phase-trial-sgn-liv1a-initiated-liv-1-positive-metastatic-breast-cancer/ Phase I Trial of SGN-LIV1A Initiated in LIV-1-positive metastatic breast cancer] ADC Review / Journal of Antibody-drug Conjugates. October 22, 2013. Last accessed October 23, 2013

=2014=

:29 September: brentuximab vedotin was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.[https://www.reuters.com/article/seattle-genetics-study-idUSL3N0RU4B920140929?type=companyNews Seattle Genetics, Takeda's cancer drug meets main goal in trial] Reuters

:8 December: Data of Brentuximab Vedotin in Diffuse Large B-cell Lymphoma presented at the Annual Meeting of the American Society of Hematology[https://web.archive.org/web/20150220071209/http://www.reuters.com/article/2014/12/09/ca-seattle-genetics-idUSnBw086255a+100+BSW20141209 Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting] Reuters

=2015=

:12 January: clinical collaboration with Bristol-Myers Squibb to evaluate combination of brentuximab vedotin and nivolumab in hematologic malignancies[https://web.archive.org/web/20150220081709/http://www.reuters.com/article/2015/01/12/wa-seattle-bristol-myers-idUSnBw125188a+100+BSW20150112 Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies] Reuters

:18 February: Supplemental Biologics License Application (BLA) for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse[http://adcreview.com/news/supplemental-bla-brentuximab-vedotin-post-transplant-hodgkin-lymphoma-patients-high-risk-relapse/ Supplemental BLA for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse] ADC Review / Journal of Antibody-drug Conjugates, Last accessed February 19, 2015

:8 June: collaboration with Unum Therapeutics to develop and commercialise its new antibody-coupled T-cell receptor (ACTR) therapies for cancer, generating up to $645 million for Unum.{{cite web|url=http://www.genengnews.com/gen-news-highlights/seattle-genetics-unum-partner-on-cancer-immunotherapies-in-up-to-645m-deal/81251361/|title=Seattle Genetics, Unum Partner on Cancer Immunotherapies in Up-to-$645M Deal - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN|date=8 June 2015}}

:31 December: Adcetris sales increase to $226 million.{{cite web| url = http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html| url-status = dead| archive-url = https://web.archive.org/web/20160329082612/http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html| archive-date = 2016-03-29| title = Seattle Genetics' ambitious plan for 12 more drugs, 100 more employees - Puget Sound Business Journal}}

=2016=

:For the year: the company was at the bottom of the Annual Top 25 Biotech Companies for the year as judged by staff of Genetic Engineering & Biotechnology News.{{Cite web|url=https://www.genengnews.com/the-lists/top-25-biotech-companies-of-2016/77900741|title=Top 25 Biotech Companies of 2016|last=Philippidis|first=Alex|date=September 26, 2016|website=Genetic Engineering & Biotechnology News|publisher=Mary Ann Liebert|access-date=23 Dec 2019}}

:28 March: the company announces it will develop 12 more drugs, employing another 100 staff.

=2020=

:The company announced its corporate name change to Seagen Inc.{{cite web |title=Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc. |url=https://www.businesswire.com/news/home/20201008005358/en/Seattle-Genetics-Inc.-Announces-Corporate-Name-Change-to-Seagen-Inc. |publisher=BusinessWire |access-date=20 January 2023 |date=8 October 2020}}

=2022=

:In July the press reported Merck & Co. was in advanced talks to acquire Seagen Inc. and was aiming to finalize a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.{{Cite web |url=https://www.reuters.com/markets/deals/merck-advanced-talks-buy-seagen-40-billion-deal-wsj-2022-07-07/ |title=Merck in advanced talks to buy Seagen in nearly $40-bln deal - WSJ |date=2022-07-06 |access-date=2022-07-31 |website=Reuters }} The expected sellout is expected to materialize in the month of August 2022 with some delay due to Merck being set to report its fiscal second-quarter earnings on July 28.{{Cite web |url=https://www.wsj.com/articles/merck-deal-for-seagen-unlikely-by-earnings-sources-say-11657920647 |title=Merck Deal for Seagen Seen as Unlikely by Earnings Release |date=2022-07-15 |access-date=2022-07-31 |website=wsj.com }}

=2023=

:In March 2023, Pfizer agreed to acquire Seagen for a total enterprise value of around $43{{nbsp}}billion. The acquisition includes the FDA approved medicines Adcetris for lymphomas, Padcev for bladder cancers, Tivdak for cervical cancer and Tukysa for breast and colorectal cancers as well as Seagen's drug development pipeline.{{cite news |last=Mishra |first=Manas |date=2022-03-13 |title=Pfizer signs $43 bln Seagen deal in cancer drug push |url=https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/ |publisher=Reuters}}

Pfizer later announced that it would abandon its plans to build a large manufacturing facility in Everett, Washington, which was scheduled to open in 2024.{{cite news |last=Geraldo |first=Renata |date=March 5, 2024 |title=Pfizer pulls plug on mammoth Seagen pharma factory in Everett |url=https://www.seattletimes.com/business/pfizer-pulls-plug-on-mammoth-seagen-pharma-factory-in-everett/ |work=The Seattle Times |accessdate=March 12, 2024}}{{cite news |last=Goldstein-Street |first=Jake |date=March 4, 2024 |title=Pfizer backs out of Everett manufacturing plant after $43B Seagen deal |url=https://www.heraldnet.com/news/pfizer-backs-out-of-everett-manufacturing-plant-after-43b-seagen-deal/ |work=The Everett Herald |accessdate=March 12, 2024}}

Product portfolio and pipeline

ADCETRIS: used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.[http://jco.ascopubs.org/content/30/18/2190.full Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study] JCO June 20, 2012 vol. 30 no. 18 2190-2196
SGN-75 (INN: vorsetuzumab mafodotin: a humanized IgG1 monoclonal antibody conjugated via a non-cleavable maleimidocaproyl (mc) linker with monomethyl auristatin F (MMAF), used in Phase I trial of relapsed or refractory renal cell carcinoma patients or non-Hodgkin lymphoma patients.[https://archive.today/20150220041042/http://www.imgt.org/mAb-DB/search.action;jsessionid=F62E9EED14D0EB13572ACC223143042F IMGT/mAb-DB SGN-75] Poiron, C. et al., JOBIM 2010, Paper 13 (2010).
ASG-5ME: product candidate for the treatment of solid tumours (targets SLC44A4 in pancreatic, prostate and gastric cancer).
Enfortumab vedotin (aka ASG-22ME, formerly ASG-22M6E): product candidate for the treatment of solid tumours (targets Nectin-4 in bladder, breast, lung and pancreatic cancer);[http://adcreview.com/enfortumab-vedotin-asg-22me-formerly-ags-22m6e-clinical-trials/ Enfortumab Vedotin (ASG-22ME, Formerly AGS-22M6E) Clinical trials] ADC Review / Journal of Antibody-drug Conjugates; Last accessed February 18, 2015[http://www.cancer.gov/drugdictionary?cdrid=708210 Anti-Nectin-4 monoclonal antibody-drug conjugate AGS-22M6E] National Cancer Institute (NCI) Drug Dictionary developed in 50-50 partnership with Astellas
SGN-CD19A: product candidate for the treatment of hematologic malignancies